In the field of small nucleic acid drugs for the treatment of liver cirrhosis, Beroni Pharmaceutical (Guangdong) Co., Ltd., a subsidiary of Beroni Group, has recently made a significant breakthrough. The team’s R&D project on “targeted treatment of liver cirrhosis using nucleic acid aptamer coupled nucleic acid targeted drugs” has won four invention patents this year.
Beroni’s scientific team has worked hard for many years to research cellular targeted tools for delivering drugs. At present, this project has completed preliminary research and animal experiments, and successfully obtained the following four invention patents: “A nucleic acid Aptamer-Wu targeting activated hepatic stellate cells and its application”, “A nucleic acid aptamer APT-Tan targeting activated hepatic stellate cells and its application”, “A screening method for nucleic acid aptamer APT8 targeting activated hepatic stellate cells”, “A screening method for nucleic acid aptamer APT-Tan targeting activated hepatic stellate cells”.
Beroni Group will adhere to increase project investment, expand R&D scale, explore new therapeutic targets, broaden indications, and continuously upgrade and optimize products. Due to the various advantages exhibited by nucleic acid aptamers, such as low molecular weight, short acquisition cycle, low cost, strong stability, easy modification, and low immunogenicity, this project undoubtedly has broad market potential and development prospects. Beroni Group is expected to achieve more breakthrough results in this field, providing patients with more and better treatment options.
